June 18, 2024

Futureality

Future Depends on What You Do

Nexalin Know-how Stories Outcomes of Scientific Examine Supporting the Therapeutic Rewards of its Gen-2, 15 Milliamp Neurostimulation Product in Managing Migraine Complications and Connected Signs or symptoms

Nexalin Technology, Inc.

Nexalin Technology, Inc.

New migraine knowledge builds on prior medical reports in depression

Migraine demo success

Migraine trial results

Migraine trial outcomes

Depression trial benefits

Depression trial results

Despair demo final results

HOUSTON, Aug. 07, 2023 (World NEWSWIRE) — Nexalin Engineering, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL NXLIW) today provided an update on the growing overall body of medical knowledge supporting the possible therapeutic positive aspects of its next-generation (Gen-2), 15 milliamp (mA) neurostimulation system, together with the outcomes of a review in patients with migraine problems, which indicated a considerable and statistically significant benefit in patients.

The scientific demo was funded by the Company’s joint venture spouse, Broader Appear Confined (“Wider”), and its related companies, and was executed at the Vertigo Centre, Office of Neurology, 2nd Affiliated Healthcare facility of Zhengzhou College.  The outcomes have been also offered in Chin J Neuromed, a peer-reviewed scientific journal in China, which concluded that repeated treatment with Nexalin’s neurostimulation unit implies a sizeable reduction in the frequency and degree of discomfort of migraine sufferers.  In addition, a powerful basic safety profile was reported.

As element of the medical research, 40 migraine people (without having migraine aura) have been dealt with at the Vertigo Centre. Sufferers were being randomly assigned 1:1 to experimental and sham groups.  Therapy was administered for 4 consecutive months with a 4 7 days abide by-up interval. Efficacy and adverse reactions had been assessed before cure, at the finish of treatment method, and at the close of follow-up, respectively.

A statistically significant enhancement was achieved throughout all key metrics, which includes Visual Analog Scale (VAS), Pittsburgh Snooze Excellent Index (PSQI), Hamilton Stress Ranking Scale (HAMA), Hamilton Melancholy Score Scale (HAMD) and Migraine-Certain Excellent of Daily life Questionnaire (MSQ) scores (see charts beneath). All of these steps are utilised as common scales in scientific practice to evaluate the severity and impact of migraine and similar indications, as effectively as the usefulness of treatment. Also, no adverse gatherings had been noticed throughout remedy in the two groups.

 

Migraine demo effects

The migraine study follows the Company’s new clinical research in depression, which shown statistically considerable improvements between sufferers.  Numerous scientific tests have indicated an affiliation in between migraines and important depressive disorder (MDD), and melancholy is estimated to impact just about 80% of all migraine sufferers.

The preceding 8-week randomized, double-blind, sham-controlled trial evaluating 100 clients with MDD, revealed in the international journal, Brain, indicated that sufferers getting procedure with the Company’s Gen-2, 15mA neurostimulation product experienced superior remission and reaction costs than the sham group. In comparison with sham procedure, practically all depressive signs or symptoms among the the active treatment confirmed sizeable improvement. What’s more, there was no major statistical big difference in adverse functions among the two groups.

Melancholy demo results                       

According to the Environment Wellness Organization (WHO), the prevalence of psychological overall health issues and situations is increasing all over the world and there has been a 13% maximize in psychological wellness ailments and other depressive problems in the past decade by itself. Notably, in 2020, among the adolescents amongst ages 12 and 17, 17% percent had a important depressive episode (MDE), and 12% experienced MDE with serious impairment in 2020, according to the United states Section of Health and fitness and Human Products and services (HHS).

Mark White, CEO of Nexalin Technology, stated, “Analysis and Marketplaces estimates the migraine and melancholy markets at approximately $3.9 billion and $11.2 billion, respectively.  We think the information we have noted in our clinical experiments give proof of likely scientific efficacy, with no any major adverse results, which is specifically noteworthy presented the escalating number of people in search of non-pharmacological therapy selections, because pharmaceuticals often occur with really negative side outcomes.  We glimpse forward to conducting supplemental medical trials in new indications – a lot of of which will be totally funded by Broader, our new JV lover.”

About Nexalin Technological know-how, Inc.

Nexalin styles and develops innovative neurostimulation goods to uniquely and properly assist combat the ongoing international mental wellbeing epidemic. All of Nexalin’s products and solutions are non-invasive and undetectable to the human human body and produced to supply aid to those people afflicted with psychological health challenges. Nexalin makes use of bioelectronic professional medical technological know-how to handle mental health issues. Nexalin believes its neurostimulation medical units can penetrate constructions deep in the mid-mind that are involved with psychological overall health disorders. Nexalin believes the further penetrating waveform in its up coming-technology equipment will generate increased affected person reaction without the need of any adverse aspect effects. The Nexalin Gen-2 15 milliamp (mA) neurostimulation unit was not too long ago authorized in China by the Nationwide Health care Products Administration (NMPA) for the treatment of sleeplessness and despair. Supplemental information about the Corporation is available at: https://nexalin.com/.

Forward-Looking STATEMENTS

This press launch contains statements that constitute “forward-hunting statements,” These statements relate to future activities or Nexalin’s future fiscal general performance. Any statements that refer to expectations, projections or other characterizations of long term functions or situations or that are not statements of historical fact (like without having limitation statements to the effect that Nexalin or its administration “believes”, “expects”, “anticipates”, “plans”, “intends” and identical expressions) should be deemed ahead looking statements that contain challenges and uncertainties which could trigger real situations or Nexalin’s actual benefits to differ materially from individuals indicated by the forward-on the lookout statements.  Ahead-hunting statements are issue to several disorders, many of which are further than the command of the Firm, which include these set forth in the Possibility Factors area of the Firm’s Report on Kind 10-K for the year ended December 31, 2022 and other filings as filed with the Securities and Exchange Fee. Copies of such filings are accessible on the SEC’s web-site, www.sec.gov. These ahead-searching statements are made as of the date hereof and may well develop into out-of-date about time. This sort of forward-searching statements are created as of the day hereof and could develop into outdated around time. The Enterprise undertakes no obligation to update these statements for revisions or improvements after the date of this release, other than as required by law.

Contact:
Crescendo Communications, LLC
Tel: (212) 671-1020
E-mail: [email protected]

Attachments